E2B Mailer: Safety Notifications Made Easy
Monitor adverse drug reactions (ADRs) outside of the scope of a full PV system
(PresseBox) - EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system.??
EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse drug reactions (ADRs) outside of the scope of a full PV system in a trial or non-interventional study. After much research and engineering time they came up with the E2B Mailer.??
The E2B Mailer is a new safety notification solution that provides an auto forward functionality of (Serious) Adverse Events in E2B and archivable format. It has the great advantage of being EDC agnostic, so it can adapt to any study and/or software.??
It has been proven to perfectly bridge the gap between a full PV and a simple reposting system. The E2B mailer is tailored to provide a streamlined way to monitor ADRs. It uses automated algorithms to detect potential ADRs and sends notifications to investigators in real-time. This ensures that potential safety issues are identified and reported promptly, reducing the risk of harm to patients. By being EDC agnostic, the safety notification tool ensures that the user can focus on conducting its NIS without having to worry about the compatibility of the ADR monitoring and reporting system.?
EvidentIQ offers highly robust, reliable, and secure applications that scale elastically and cost-effectively. The E2B mailer offers high reliability (99.05%), PDFs highlighting changes, encryption at rest and in transit, E2B attachments to connect to PV Systems, and it also includes special use cases for non-interventional studies.?
EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.
EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, the UK, Italy, Canada, Japan and China.
Unternehmensinformation / Kurzprofil:
EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.
EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, the UK, Italy, Canada, Japan and China.
Datum: 05.05.2023 - 02:42 Uhr
Sprache: Deutsch
News-ID 683006
Anzahl Zeichen: 0
contact information:
Contact person: David Renzelmann
Town:
Hamburg
Phone: 089452277500
Kategorie:
Manufacturing & Production
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"E2B Mailer: Safety Notifications Made Easy"
steht unter der journalistisch-redaktionellen Verantwortung von
EvidentIQ Group GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
